Disclaimer: Q-PULSE survey data represent the aggregate responses of a panel of epileptologists to questions to gather their opinions and/or approaches to issues in clinical epilepsy care. These data are not derived from a clinical trial or scientific study. Q-PULSE survey results are not intended to establish a community standard of care, replace a clinician's medical judgment, or establish a protocol for all patients.
Introduction
Our understanding of the burden epilepsy can impose in our patients has deepened in recent years as we have become progressively more aware of the many aspects of the condition, which severely affect our patient's life beyond the impact of seizures. The prevalence of psychiatric comorbidities, particularly depression and anxiety, in persons with epilepsy (PWE) is reported to be higher than in the general population with an odds ratio of 1.3 to 2 .0 for depression and 1.6 to 2.4 for anxiety (1, 2) . Thanks to copious research generated by epileptologists, psychologists and other mental healthcare providers and organizations, general neurologists and epileptologists alike can today better appreciate the importance of early identification of psychiatric comorbidities in PWE. However, there seems to be less of a consensus regarding how to screen for, identify, and follow psychiatric comorbidities in our patient, as well as how and who should treat these conditions within the boundaries of the epilepsy clinic.
This Q-PULSE survey was conceived by Heidi M. Munger Clary, MD, MPH, and the AES Psychosocial Comorbidities Workgroup, and asked questions about approaches and barriers to assessing depression and anxiety in epilepsy patients.
The survey was open from February 19 to March 13, 2016, and 102 responses were received out of 169 Q-PULSE panel members, for a response rate of 60%. Respondents were asked to indicate their preferences and practices regarding diagnosis and management of a patient with depression and anxiety as well as the barriers they identify for actively screening patients in the clinic for these psychiatric comorbidities.
Sixty percent is a good respondent rate for a survey conducted by email; however, it may represent a selection bias.
Physicians who feel less comfortable dealing with psychiatric comorbidities in the office may have been less keen on addressing this type of questionnaire. I can only speculate that epileptologists convinced of the need to address mental health issues with their patients may have been the ones responding to this Q-PULSE.
Survey Results
When presented with a patient with symptoms of depression, 70% of respondents would perform further screening to clarify the diagnosis and severity of the condition, and 48% chose to refer the patient to a psychiatric clinic (note that respondents could choose more than one option). Approximately 60% of respondents felt comfortable prescribing an antidepressant, 90% still thought a referral to a mental healthcare provider (52% to psychiatry, 39.2% to a mental healthcare professional) was in order. Only 12% seem to think the primary care provider would be better equipped to address this problem.
When faced with a patient with anxiety, epileptologists seem to be less keen on initiating management. Only 53.9% of respondents would perform further screening in the office, 58.8% chose to refer the patient to a psychiatric clinic. Only 33.7% of respondents felt comfortable prescribing an anxiolytic, 95.1% still thought a referral to a mental healthcare provider (61.4% to psychiatry, 33.7% to a mental healthcare professional) was in order. Still 14.9 % of respondents seem to think the primary care provider would be better equipped to address the issue.
Most respondents routinely address depression (65.7%) at initial visit and at every follow-up visit, but are less likely to ask about anxiety (47.5%). Some providers reported addressing psychiatric comorbidities only once a year regarding depression (14.7%) and anxiety (50.5%) or only when prompted by the patient or family member (15.7% depression, 34.7% anxiety).
Most providers prefer to include screening questions as part of their clinical interview (62.7% depression and 68.3% anxiety) and only 11.8% administer and score a validated screening instrument for depression (11.8%) and anxiety (4.9%).
The most frequently used instruments were the Neurologic Disorder Depression Inventory for Epilepsy (NDDI-E; 63.2% of respondents to this question) for depression and Generalized Anxiety Disorder 7-item scale (GAD -7; 87.5% of respondents to this question) for anxiety.
Multiple barriers were identified by respondents regarding screening for depression and anxiety in the clinic. The most frequent ones were related to lack of available mental healthcare providers: "Inadequate availability of psychiatrist in my area for referral of patients with these symptoms" (55.4%), and "Inadequate availability of counseling/psychotherapy services in my area for patient referral" (53.5%) were followed by answers expressing time concerns: the instruments are too long (36.6%), not having enough time to administer the screening instrument in the clinic (53.5%), not enough time for the clinic staff to do it (40.6%), and not enough clinic time to address the issues the instruments may uncover (24.8%) were followed in frequency by insurance-(42.6%), cost-(12.9%), and personnel-(7.9%) related concerns. A third of respondents recognized not having enough information regarding which instruments are the best to use (30.7%) or being uncomfortable initiating treatment for symptoms related to these conditions (24.8%). A fifth of respondents report no need for screening instruments in their practice.
Discussion
The relationship between seizures and the most common psychiatric comorbidities in epilepsy (e.g., mood and anxiety disorders) is complex and has been found to be bidirectional. The goals of achieving better seizure control, gaining employment, and improving the quality of life in PWE are closely linked to the identification and management of these psychiatric comorbidities (3). The Q-PULSE respondents recognize this relationship and are willing to engage in the identification and some, in the management of the psychiatric symptoms their patients present them with. A majority of the respondents already assess their patients for depression and anxiety at least once a year and less frequently at every clinic visit. Most of the surveyed epileptologists prefer to incorporate the screening for depression and anxiety into their interview dur-ing the clinic visit and, not surprisingly, complain of not having enough time to fully assess the extent of the problem or to deal with the findings their interview may uncover.
Only a fraction of these providers use and score validated scales such as the Patient Health Questionnaire (PHQ), NDDI-E, Hospital Anxiety and Depression Scale (HADS), and GAD-7 for the assessment of depression and anxiety in the clinic and by doing so, may be depriving themselves and their patients of a valuable opportunity for diagnosis and intervention. Screening scales can be applied to all patients, independent of the presence of symptoms; they may uncover psychiatric symptoms that are not evident on the surface during a symptoms-based interview. Most of these scales are self-administered by the patient and quick to complete in the waiting room before the patient is called into the office. This practice can address the time-related concerns expressed by the survey respondents.
The scales are free for all clinicians to use, several (NDDI-E and GAD-7) are available on several languages and do not require the engagement of trained personnel (4). They have been validated in PWE, are easy to score, and allow the physician to decide if he or she needs to spend valuable clinic visit time expanding on the endorsed psychiatric symptoms or just acknowledge the negative results and move on to other issues.
Positive screening results may pose a challenge. But our concern for our patients' wellbeing prevents us from hiding our heads in the sand and from refusing to ask the necessary questions just because we may be concerned that we may not always know how to deal with the answers. Implementing the use of screening questionnaires to identify depression and anxiety symptoms has to invariably be linked to a protocol that can provide potential solutions. Given the enormous gap in mental healthcare access within our patient population, the only answer cannot be a referral to a psychiatrist or other mental healthcare provider. Access to quality mental healthcare is extremely limited and subjected to restrictions, such as health insurance constrains, long waiting times, and the undeniable apprehension and stigma that many of our patients are faced when considering the possibility of seeing a psychiatrist or other mental health care professional.
Fortunately, more than half of the surveyed epileptologists are willing to make the diagnosis and start treatment for depression in the office. One-third of them are willing to start treatment for anxiety as well and hopefully follow the psychi-atric symptoms of their patients in the clinic at least until they get to establish care with a mental healthcare provider. The benefits of this approach are many and including achieving better seizure control (5) .
As we move to a model where depression and anxiety are not considered added complications that happen to our patient population but rather frequent manifestations of the epilepsy itself, we may further embrace the idea that adequate epilepsy care must include the management of all neurological, physical, and psychiatric expressions of the disease and that we, the epileptologists, should equip ourselves with the tools to make the diagnosis, initiate management, and provide proper follow-up.
Screening instruments and management guidelines have the ability to transform the knowledge we have gained into the prevalence and impact of psychiatric comorbidities in epilepsy into actual interventions with the potential of effectively improve our patient's quality of life and even our understanding of their condition. Further research and educational initiatives like the ones which have taught us about the coexistence of these comorbidities should be put in place to further educate neurologists and epileptologists regarding their treatment.
